We serve Chemical Name:1-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxy)phenyl]ethanone CAS:887576-99-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![1-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxy)phenyl]ethanone](https://a.dearchem.com/CAS2/887576-99-0.png)
Chemical Name:1-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxy)phenyl]ethanone
CAS.NO:887576-99-0
Synonyms:1-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxy)phenyl]ethanone
Molecular Formula:C18H18O2
Molecular Weight:266.33400
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:26.30000
Exact Mass:266.13100
LogP:4.56030
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxy)phenyl]ethanone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxy)phenyl]ethanone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxy)phenyl]ethanone Use and application,1-[4-(5,6,7,8-tetrahydronaphthalen-2-yloxy)phenyl]ethanone technical grade,usp/ep/jp grade.
Related News: “From the new company, we’ll be able to provide customers with invaluable access to high-quality sterile fill and finish capacity, which is in huge demand globally,” Recipharm CEO Marc Funk said in a release. Dibenzo[b,e][1,4]dioxin, 3-bromo-1,7,9-trichloro- manufacturers The growing use of biocatalysis in pharmaceutical chemistry promises to deliver on this need, while also offering substantial cost savings and faster time to market for urgently needed therapeutics. 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chloro-3-pyridinyl)- suppliers For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 were 13.5% SLE Disease Activity Index (SLEDAI), 15.5% British Isles Lupus Assessment Group index (BILAG) and 15.6% modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI). For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG and 12.6% joint response. 7-((4-(4-bromophenyl)-5-mercapto-4H-1,2,4-triazol-3-yl)methoxy)-4-methyl-2H-chromen-2-one vendor & factory.
